Recurrent gene fusions involving several members of ETS transcription factor family (ERG, ETV1, ETV4 or ETV5) were found to be the most frequent genetic alterations in prostate cancer, which can be detected in as many as 50%–70% of prostate cancer samples [16,17]. This evidence concerns the gene ERG and prostate carcinoma.